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Abstract: Shikimate kinase (SK), the fifth enzyme of the 
aromatic amino acid biosynthesis, is a recognized target for 
antibiotic drug discovery. The potential of the distinct dynamic 
apolar gap, which isolates the natural substrate from the solvent 
environment for catalysis, and motion of Mycobacterium 
tuberculosis and Helicobacter pylori SK enzymes, which was 
observed by Molecular Dynamics simulation studies, was 
explored for inhibition selectivity. The results of our biochemical 
and computational studies reveal that the incorporation of bulky 
groups at position C5 of 5-aminoshikimic acid and the natural 
substrate enhances the selectivity for the H. pylori enzyme due 
to key motion differences in the shikimic acid binding domain 
(mainly helix 5). These studies show that the less exploited 
motion-based design approach, not only is an alternative 
strategy for the development of competitive inhibitors, but could 
also be a way to achieve selectivity against a particular enzyme 
among its homologous ones. 
Introduction 
Resistance to current antibiotics in pathogenic bacteria is a huge 
worldwide challenge in clinical settings because some 
pathogens have even become resistant to multiple types of 
antibiotics.[1-8] Of particular concern are patients with a weak 
immune system undergoing surgery, cancer chemotherapy and 
dialysis, amongst others, for whom our ability to deal with 
secondary infections is crucial. The increased occurrence of 
hard to treat bacterial infections has mainly been determined by: 
(1) the inappropriate and excessive use of these drugs in 
medicine, veterinary medicine and agriculture over the years; (2) 
the reduced output in the development of novel antibiotics by the 
pharmaceutical industry over the past decades;[9-10] and (3) the 
inherent tendency of bacteria to survive in hostile 
environments.[11] It is therefore a matter of urgency to develop 
new antibacterial agents and approaches to face the challenge 
of multidrug resistance. 
In recent years a great deal of research has been devoted to the 
search for unexplored key bacterial functions for the 
development of novel antibiotics with a new mechanism of 
action. In particular, those proteins encoded by essential 
bacterial genes appear to be a good starting point for the design 
of compounds that deal with bacterial viability (antibiotics). Our 
research group is exploring the potential of shikimate kinase (SK, 
EC 2.7.1.71, aroK gene), the fifth enzyme of the aromatic amino 
acid biosynthesis, which is also known as the shikimic acid 
pathway.12 This enzyme attracted our attention because it has 
proved to be essential (aroK gene) in relevant pathogenic 
bacteria and it does not have any counterpart in human cells.13,14 
SK is a recognized target for tuberculosis, infections caused by 
the ESKAPE pathogen Pseudomonas aeruginosa, which is 
nowadays resistant to almost all antibiotics, the foodborne 
diseases caused by Escherichia coli and for the treatment of 
Helicobacter pylori infections, which cause gastric and duodenal 
ulcers and in some cases stomach cancer.  
 
Scheme 1 Enzymatic conversion catalyzed by SK. 
SK is a magnesium dependent enzyme that catalyzes the 
stereospecific phosphorylation of the C3 hydroxyl group of 
shikimic acid (1) to provide shikimate-3-phosphate (2) by using 
ATP as a cofactor (Scheme 1). By a combination of NMR and 
computational studies, we have shown recently that the 
conversion catalysed by SK involves a dissociative phosphoryl-
transfer mechanism.[15] The reaction is initiated with the 
formation of a metaphosphate intermediate (PO3
) by cleavage 
of the γ O-P bond in ATP, followed by subsequent nucleophilic 
attack of the C3 hydroxyl group. SK has two binding sites, one 
for shikimic acid (1), and another for the cofactor (ATP), with 
different key interactions in both cases. SK has three domains: 
(1) the CORE domain that contains five stranded parallel -
sheets and the P-loop, which forms the binding site for ATP and 
ADP; (2) the LID domain, which closes over the active site and 
has residues that are essential for the binding of ATP and 
catalysis; and (3) the substrate binding (SB) domain, which is 
responsible for the recognition and binding of 1. 
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Most of the approaches used in the structure-based design of 
inhibitors of this enzyme (and for other targets) are based on 
docking or virtual screening studies using the available crystal 
structures.[16-19] In this case, the disposable structures are binary 
complexes of the enzyme with one of the substrates (ATP or 1) 
in the active site or ternary complexes with shikimic acid (1) and 
ADP.[20-22] As one would expect for enzyme complexes with the 
substrate(s) or product(s), these structures show a closed 
conformation of the active site. As a consequence, the outcomes 
of these studies are governed by this arrangement. In these 
cases, inhibition is achieved by ligands that stabilize the closed 
arrangement in a similar way to the Michaelis complex (ES). 
Therefore, the size and conformation of the ligands would be 
determined by the space available in the employed crystal 
structures. However, enzymes are ‘dynamic’ systems that are 
able to adopt diverse conformations during catalysis and this 
could also be exploited in inhibitor design since the flexibility is 
essential for catalysis. Thus, in the absence of substrate, they 
adopt an open conformation to receive the substrate to be 
transformed. Once the substrate enters the active site, a flexible 
substrate-covering loop closes the active site over the substrate 
for conversion. Finally, the product is expelled from the active 
site and the inactive open conformation is recovered to start the 
next cycle. It seems reasonable that for enzyme inhibitor design, 
in addition to stabilizing a closed disposition of the active site 
that prevents the entry of the substrate(s), disabling the closure 
of the active site for catalysis could also be an interesting 
alternative strategy. This motion-based approach allows the 
design of ligands that target additional cavities generated during 
this motion but have limited (or no) access in the closed 
conformation. The success of this approach could also benefit 
from the recent advances in computational methods that have 
consolidated their value as important complementary tools that 
can assist in the elucidation of the essential motions required for 
catalysis. By using this less exploited ‘motion-based design 
approach’, we report here competitive inhibitors of the SK 
enzyme that block the closure of the active site by reducing the 
flexibility of the LID and SB domains, which are required for 
catalytic turnover. 
Recently, we reported our first approach to achieve the 
stabilization of the open conformation of the active site.[23] This 
study was carried out with 5-O-benzyl-substituted shikimic acid 
derivatives 3a and 3b, which bear 3-nitrobenzyl and 5-
benzo[b]thiophenylmethyl groups, respectively (Figure 1).  
 
Figure 1 Selected 5-O-benzyl-substituted shikimic acid analogues reported 
previously as reversible competitive inhibitors. Ki against Hp-SK and Mt-SK are 
also included. 
These compounds proved to be reversible competitive inhibitors 
of SK from M. tuberculosis (SK-Mt) and from H. pylori (SK-Hp), 
with Ki values below Km, specifically 43 µM and 10 µM for SK-Mt 
and 560 nM and 460 nM for SK-Hp, respectively. In both cases 
the aromatic moiety was incorporated to interact with the 
dynamic apolar pocket generated by several lipophilic residues 
located in -helices 2, 3 and 5 (SB domain) surrounding the 
C5 hydroxyl group of 1, which isolates the natural substrate from 
the solvent environment (Figure 2).  
 
Figure 2 Detail view of the apolar pocket in the SB domain of the Mt-SK (A) 
and Hp-SK (B) enzymes. Relevant side chain residues are shown and 
labelled. 
On studying the essential motion of the SK-Mt and SK-Hp 
enzymes by Molecular Dynamic (MD) simulation studies on the 
enzyme product complexes (SK/ADP/2) (Figure 3),[23-24] we 
observed that: (1) as expected, a large opening of the LID 
domain (up to 10 Å) is required in both cases; (2) surprisingly, 
an opening of the SB domain, which is composed of three -
helices (2, 3 and 5), is also necessary in the two enzymes; 
and (3) more importantly, there are significant differences in the 
opening of the SB domain between the two enzymes (Figures 
3A and 3C vs 3B and 3D). Moreover, the examination of the 
vibrational modes calculated by using principal component 
analysis as implemented in Amber also showed these clear 
differences (Figures 3E vs 3F) (see experimental section and 
Figure S1). A synchronous and large opening of the three -
helices 2 (7 Å), 3 (10 Å) and 5 (6 Å) takes place for the 
Mt-SK enzyme, but for the Hp-SK enzyme an asynchronous and 
more reduced opening was observed, mainly in helix 5. In 
addition, for Mt-SK the process is very fast since in less than 3 
ns at 25 ºC the product is released from the active site, but for 
Hp-SK the process is very slow as large changes are not 
observed until over 20 ns after heating at 50 ºC. These findings 
suggest that: (1) the opening of the LID and SB domains is wide 
enough to accommodate bulky groups in position C5 of shikimic 
acid (1) and this is able to promote extra binding interactions 
with this important part of the active site and may provide 
inhibitors with improved inhibitory potencies; and (2) these 
modifications would be more efficient for the H. pylori enzyme. 
 







Figure 3 Shikimate kinase motion. (A,B) Overall view of the motion required for product release from the active site of Mt-SK (A) and Hp-SK (B) obtained by MD 
simulation studies. The position of 2 at the beginning and the end of the simulation is shown. Significant changes were not observed in the position of ADP. The 
LID and SB domains of Mt-SK (A, green and red, respectively) and of Hp-SK (B, blue and orange, respectively) are highlighted. (C,D) RMSD plots for the protein 
backbone (Cα, C, N, and O atoms) calculated per residue in the Hp-SK/ADP/2 (A) and Mt-SK/ADP/2 (B) complexes obtained from MD simulations studies. (E,F) 
Overall view of the SK motion obtained by examination of the vibrational modes. The main vibrational modes for Mt-SK (E) and Hp-SK (F) enzymes are presented. 
To explore this hypothesis, we report here the synthesis and 
inhibitory properties against Mt-SK and Hp-SK of several N,N-
dibenzyl-5-aminoshikimic acid analogues, namely compounds 4, 
that incorporate two aromatic moieties at C5 of 5-aminoshikimic 
acid (Figure 4). The corresponding N-benzyl-5-amino derivatives 
(compounds 5) were also synthesized to evaluate the effect of 
replacing an ether linkage by an amine one in 3. The binding 
modes of the reported compounds with the two SK enzymes 
were initially studied using GOLD 5.2[25] and diverse open forms 
of the active site obtained by MD simulations studies. The 
stability was then further analyzed by MD simulation studies. 
Results and Discussion 
Synthesis of Compounds 45 
The synthesis of N,N-di(benzo[b]thiophen-5-ylmethyl)amine 
derivative 4a, N,N-di(naphth-2-ylmethyl)amine derivative 4b and 
N,N-di(3-bromo-1H-indol-5-ylmethyl)amine derivative 4d was 






carried by alkylation of amine 7 as outlined in Scheme 2. 
Staudinger reduction of azide 6[23] provided amine 7, which was 
treated with 5-(bromomethyl)benzo[b]thiophene, 2-
bromomethylnaphthalene, or tert-butyl 5-(bromomethyl)-1H-
indole-1-carboxylate in the presence of potassium carbonate to 
give the dialkyl derivatives 8. Finally, deprotection of the methyl 
ester afforded the desired compounds 4. 
 
Figure 4 Target compounds 45. 
N-(naphth-2-yl)methylamine derivative 5b and N-(indol-5-
yl)methylamine derivative 5c were prepared by reductive 
amination of 2-naphthaldehyde or indole-5-carboxaldehyde, 
respectively, with protected amine 9, which was prepared by 
protection of previously reported diol 6[23] followed by Staudinger 
reduction of the resulting protected azide 8 (Scheme 2). Acetal 
deprotection of the resulting compounds 10 followed by basic 
hydrolysis of the resulting esters 11 gave the N-5-benzylamino 
shikimic acid derivatives 5b and 5c, respectively. 
Inhibitory Activity 
The inhibitory properties of compounds 4–5 against both SK 
enzymes were tested. Enzyme activity was measured by UV 
monitoring of ADP formation by coupling the released ADP to 
the oxidation of NADH using pyruvate kinase (PK) and lactate 
dehydrogenase (LDH) as coupling enzymes. All of the 
compounds, which were found not to be substrates for this 
enzyme, were assayed in the presence of shikimic acid (1) and 
ATP for their inhibitory properties against Mt-SK and Hp-SK. 
Most of the compounds proved to be reversible competitive 
inhibitors of both enzymes. The inhibition data (Ki), which were 
obtained from Dixon plots (1/v vs [I]), are provided in Table 1. 
The results show that the replacement of the ether linkage in 3 
by an amino one, compounds 5, causes a large decrease in 
inhibitory potency (Table 1, entry 2 vs 6). However, the 
incorporation of a second benzyl group in 5, N,N-dibenzylamine 
derivatives 4, provided compounds with improved inhibitory 
activities (Table 1, entries 3–5). Surprisingly, the effect of the 
type of aromatic ring seems to follow different trends for the two 
enzymes. For example, the least potent inhibitor of series 4 
against Mt-SK, i.e., compound 4b (Ki = 48 µM) with a 
naphthalene moiety, proved to be the most potent against Hp-
SK (Ki = 300 nM). At the same time, the most potent inhibitor 
against Mt-SK, compound 4d (Ki = 8.2 µM), was the worst 
against Hp-SK (Ki = 8.7 µM). In an effort to obtain further details 
of the binding interactions responsible for the inhibitory activity 
and to gain a better understanding of this trend, the binding 
modes of compounds 4–5 with Mt-SK and Hp-SK were studied. 
The results of these studies are discussed below. 
 
Scheme 2 Synthesis of compounds 45. Reagents and conditions: (a) 
PPh3, H2O, THF, Δ. (b) ArCH2Br, K2CO3, CH3CN, RT. (c) K2CO3, MeOH 
(aq, 75%), Δ. (d) NaOH, THF, RT. (e) Me2C(OMe)2, CSA, Δ. (f) ArCHO, 
NaBH3CN, NaOAc, 4Å MS, MeOH, RT. (g) HCl (6 M), EtOH, 60 ºC. 
Binding Mode 
Molecular docking using GOLD 5.2[25] was initially carried out 
with diverse inactive open forms of the SK active site, which 
were obtained from several poses of the MD simulation of: (a) 
Hp-SK/ADP/2 (50 ns)[23] and (b) Mt-SK/ATP/(6R)-6-
hydroxyshikimic acid (10 ns).[24] Poses in which the LID and SB 
domains were open, but in which the essential arginine for 
substrate recognition, Arg132/Arg136 (in H. pylori and M. 
tuberculosis, respectively), had not suffered large displacements 
were chosen. Specifically, snapshots from the 1020 ns period 
of (a) and the 57 ns of (b) were selected. The proposed binding 
modes were further analyzed by MD simulation studies (50 ns). 
 






Table 1. Ki (µM) values for compounds 35 against Hp-SK and Mt-SK
[a]
 





0.56 ± 0.05 43 ± 1 
2
24
 3c naphth-2-yl 1.80 ± 0.10 22 ± 1 
3 4a benzo[b]thiophen-5-
yl 
5.20 ± 0.40 24 ± 2 
4 4b naphth-2-yl 0.30 ± 0.02 48 ± 5 
5 4d (3-bromo)indol-5-yl 8.70 ± 0.50 8.20 ± 0.40 
6 5b naphth-2-yl 181 ± 11 >2000 
7 5c indol-5-yl 455 ± 5 >2000 
[a] Assay conditions: Tris.HCl (100 mM, pH 7.7), ATP (2.5 mM), NADH (0.2 
mM), PEP (1 mM), MgCl2 (5 mM), KCl (0.1 M), lactate dehydrogenase (2 
units), pyruvate kinase (2.8 units), 25 ºC. Km (1, Mt-SK) = 544 µM. Km (1, 
Hp-SK) = 39 µM. 
The replacement of the ether linkage in compounds 3 by an NH 
linkage (secondary amine), which should improve the solubility 
of the compounds in water, provided ligand poses in which the 
benzyl moiety was located close to Asp33/Asp34 (in H. pylori 
and M. tuberculosis, respectively). Based on the results of 
structural studies it was suggested that this residue would act as 
a general base to deprotonate the C3 hydroxyl group in 1 for 
nucleophilic attack.[20] This behaviour of compounds 5 is due to 
an electrostatic interaction between the protonated amino group 
of the ligands and the carboxylate group of Asp33/Asp34. As a 
consequence, the benzyl moieties would be located outside the 
apolar pocket as desired. On the other hand, N,N-dibenzylamine 
derivatives 4 were found to bind in the active site of the two SK 
enzymes, with the aromatic moiety interacting with the apolar 
pocket of the SB domain as desired. It is important to highlight 
that the incorporation of a second benzyl group on the C5 
nitrogen atom in 5 is crucial, not only to establish extra apolar 
interactions within the pocket, but also to lower the basicity of 
the amino group and therefore avoid protonation under neutral 
conditions. A positive charge would not be stabilized by this 
apolar pocket (Figure 2). 
The results of our computational studies reveal that N,N-
dibenzylamine derivatives 4 would stabilize a very open 
conformation of the LID and SB domains (Figure 5). The 
analysis of the variation of the relative distance between 
selected residues in the LID and SB domains in the Hp-
SK/ATP/Mg2+/L (L = 3a and 4b) and Mt-SK/ATP/Mg2+/L (L = 3b 
and 4d) complexes during the whole MD simulation shows that 
compounds 4 stabilize a more open conformation of the two 
domains than previously reported inhibitors 3a and 3b. For Hp-
SK, Arg116, Pro117 and Leu118 located in the LID domain and 
Arg45, Phe48, Glu53 and Glu49 of the SB domain were selected 
(Figure 5A). For Mt-SK, Arg117, Pro118 and Leu119 located in 
the LID domain and Ile45, Ala46, Phe49 and Glu54 of the SB 
domain were selected (Figure 5B). Moreover, the analysis of the 
root-mean-square deviations (RMSD) for the protein backbone 
(Cα, C, N, and O atoms) calculated in the SK/ATP/Mg2+/4 
complexes obtained from MD simulations studies revealed their 
stability (Figure S2). 
Remarkably, the stabilization of the open conformation by N,N-
dibenzylamine derivatives 4 occurs in quite distinct manners for 
the two enzymes (Figure 6). In general, for the Mt-SK enzyme, 
the two aromatic rings would be located in close proximity and 
act as separating clamps for the two domains. In contrast, for 
the Hp-SK enzyme, one of the aromatic rings would be located 
in the base of the active site and the other between the two 
domains in an arrangement similar to the wings of a butterfly. 
We consider that these differences are a consequence of the 
intrinsically different motions of the two enzymes and therefore 
of the dissimilar ‘generated gap’ that is achieved when the active 
site opens. As mentioned previously, whereas the active site of 
Mt-SK opens like an accordion for product release, the H. pylori 
site undergoes a much smaller twist that mainly involves α-helix 
α5. This causes a significant difference in the available 
‘generated gap’. The fact that the least potent inhibitor of the 
N,N-dibenzylamine series against Mt-SK, i.e., compound 4b (Ki 
= 48 µM), is the most potent one against Hp-SK (Ki = 300 nM) 
can be explained by this distinct binding mode, as discussed 
below. 
 










/4d (F) enzyme complexes during whole simulation. (A) 
For Hp-SK, the distances were calculated between the CA atoms of Arg116 
and Arg45, the CA atoms of Pro117 and Phe48, the N atom of Pro117 and the 
CA atom of Arg45, the CA atoms of Leu118 and Glu53 and the CA atoms of 
Pro117 and Glu49. (B) For Mt-SK, the distances were calculated between the 
CA atoms of Arg117 and Ile45, the CA atoms of Pro118 and Phe49, the N 
atom of Pro118 and the CA atom of Ala46, the CA atoms of Leu119 and Glu54 
and the CA atoms of Arg117 and Ala46. 








Figure 6 Binding mode of N,N-dibenzylamino derivatives 4d (A,B) and 4b (C,D) obtained by docking and MD simulation studies in the active site of Mt-SK (wheat) 
and Hp-SK (gray) enzymes, respectively. The poses showed for ligands 4d and 4b correspond to snapshots after 30 ns of MD simulation. (B,D) Conformational 
changes in the LID and SB domains of the SK enzymes caused by the binding of compounds 4d and 4b. The closed active form [PDB codes 2IYQ (Mt-SK) and 
3MUF (Hp-SK)] and the inactive open arrangement of the SK enzymes are compared. Relevant side chain residues are shown and labelled. Cation-π (blue) and 
lipophilic (magenta) interactions between ligands and the enzyme residues are shown. 
The binding mode of the most potent inhibitor against Mt-SK, 
compound 4d, is shown in Figures 6A and 6B. The two indole 
moieties in 4d would intercalate the LID and SB domains. This is 
achieved by a set of favourable lipophilic interactions with 
several apolar residues within the two domains. In particular, 4d 
interacts with the side chains of Pro118, Val116 and Arg117, 
which are located in the LID, and with Phe49, Ile45, Phe57 and 
Glu54, which are located in the SB domain. The aromatic 
moieties would be located between Arg117 and Glu54. The 
essential arginine would interact with one of these aromatic rings, 
mainly by CH-π interactions between the Arg117 carbon side 
chain and the indole ring, and the second one would have apolar 
interactions with the carbon side chain of Glu54. Cation-π 
interactions between the guanidinium group of Arg117 and the 
indole rings were not observed for 4d. Moreover, unlike N,N-
dinaphthylamine derivative 4b and N,N-dibenzothiophenylamine 
derivative 4a, which proved to be about 6-fold and 3-fold less 
potent than 4d, respectively, the position of the indole moieties 
is very stable during the simulation, which might account for the 
higher inhibitory potency. The binding free energies were 
calculated using the MM/PBSA[26] approach in implicit water 
(generalized Born, GB) as implemented in Amber. Compound 
4d has a binding free energy that is –11.7 kcal and –8.7 kcal 
lower than those of 4b and 4a, respectively (Table S1). It seems 
that the inductive effect resulting from the incorporation of the 
bromo-substituent in the C3 position of the indole ring enhances 
the binding affinity with the aforementioned residues, in 
particular with the essential arginine. 






The N,N-dinaphthylamine derivative 4b would bind in the active 
site of the Hp-SK enzyme with one of the naphthalene moieties 
located in the base of the active site and the other positioned 
between the LID and SB domains (Figures 6C and 6D). The 
position of the latter is controlled by a strong cation-π interaction 
with the essential arginine in addition to several apolar contacts 
with Phe48, Val44 (CH-π) and Arg45 (carbon chain). The 
second aromatic ring would be surrounded by favourable apolar 
interactions with several conserved residues of the active site. 
Specifically, this unit interacts with the main chain of Gly79, 
Gly80 and Gly81, the carbon side chains of Asp33 and Glu60 
and the side chain of Ile82. Moreover, the C3, C4 and C5 CH 
groups on the cyclohexene ring in 4b would establish several 
apolar interactions with the side chain of Met10. All of these 
favourable interactions anchor the ligand in the active site and 
fix the open inactive conformation of the active site, which 
remains stable during the whole simulation. The key interaction 
that explains the marked increase in the inhibitory potency of 
compound 4b (Ki = 300 nM) when compared with the other two 
analogues of the series (Ki = 8.7–5.2 µM) is not only the 
interaction with the essential arginine but also the large 
conformational change that positions its guanidinium group far 
from the centre of recognition of the cofactor. The calculated 
free energies also showed a good correlation with the 
experimental data. For instance, compound 4b has a binding 
free energy that is –12.3 kcal lower than that of 4d (Table S1). 
Conclusions and Final Remarks 
Diverse reversible competitive inhibitors of shikimate kinase  a 
recognized target for antibiotic drug discovery against relevant 
pathogenic bacteria – were designed based on the essential 
enzyme motion. The potential of the distinct ‘generated apolar 
gap’ and motion of M. tuberculosis and H. pylori shikimate 
kinase enzymes, which was observed in previously reported MD 
simulation studies of the enzyme/products complexes,[23] was 
explored for inhibitor design and selectivity. To this end, several 
5-aminoshikimic acid derivatives that incorporate one or two 
bulky groups in the C5 amino group were synthesized and 
tested against the two enzymes. 
Compounds 4, which contain an N,N-dibenzylamine moiety, 
were the best inhibitors for both enzymes but with different 
trends for the two SK. N,N-Dinaphthylamine derivative 4b was 
the most potent for the Hp-SK enzyme, with a Ki value of 300 nM. 
This represents an improvement on the previous results 
obtained with shikimic acid derivatives 3a and 3b, which bear an 
O-benzyl group in position C5, and 4b is the most potent 
inhibitor reported to date against the SK enzyme. For the Mt-SK 
enzyme, the N,N-diindolylamine derivative 4d was the best 
compound, with a Ki value of 8.2 µM, and this has similar 
inhibition potency as previously reported 3-nitrobenzyl derivative 
3b. In contrast, replacement of the ether linkage in 3 by an 
amino one, compounds 5, causes a large decrease in inhibitory 
potency. The incorporation of the second benzyl group on the 
C5 nitrogen atom in 5 is crucial, not only to establish extra 
apolar interactions within the pocket, but also to lower the 
basicity of the amino group and therefore avoid protonation 
under neutral conditions. Compound 4b is 160-fold higher 
inhibitory potency against Hp-SK than Mt-SK. 
Docking and MD simulation studies were performed in order to 
provide some rationale for the relative potencies of the inhibitors, 
the trends observed and to obtain further details of the binding 
mode of the inhibitors. The N,N-dibenzylamine derivatives 4 
would stabilize an open conformation of the LID and SB 
domains, albeit in quite a distinct manner for the two enzymes. 
Whereas for Mt-SK the two aromatic rings would bind in the 
active site with the two aromatic rings in close proximity and 
acting as separating clamps of the two domains, in the case of 
Hp-SK one of the aromatic rings would be located in the base of 
the active site and the other between the two domains. In both 
cases, however, the interaction of the essential arginine with 
only one of the aromatic rings through a set of favourable apolar 
interactions with this ‘dynamic apolar pocket’ seems to be crucial 
to enhance the inhibition potency of the ligands. 
The results of our biochemical and computational studies reveal 
that the more parsimonious motion and the narrow opening of 
the SB domain of Hp-SK, mainly focused in helix 5, makes this 
motion-based design approach with the scaffold identified here, 
compounds 4, more efficient for the H. pylori enzyme than for 
the M. tuberculosis one. The more limited flexibility of the SB 
domain in Hp-SK, i.e., its lower induced-fit adaptability, favours 
the conformational changes resulting from the incorporation of 
bulky groups at position C5 of the natural substrate having a 
more pronounced effect. Taking into account our MD simulation 
studies, which show that for the Mt-SK enzyme the opening of 
the active site takes place in a similar way to the movement of 
an accordion, the incorporation of additional apolar groups in the 
scaffold reported here should provide more potent inhibitors 
against the M. tuberculosis enzyme. Studies to validate this 
hypothesis are currently in progress in our laboratories. These 
studies also show that the motion-based design, not only is a 
good and alternative strategy for the development of competitive 
inhibitors, but could also be a strategy to achieve selective 
inhibitors against a certain enzyme among its homologous ones. 
By using this approach, (1) the presence in the selected pocket 
of residues with markedly different properties would not be 
required, and (2) as the essential motion for catalysis is blocked, 
the effects of changes on residues to avoid the inhibition 
(resistance) should have a less pronounced effect. It is important 
to highlight that the apolar pocket surrounding the C4 and C5 
hydroxyl groups of the natural substrate targeted in this 
approach is quite conserved (Figure 2).  
Experimental Section 
General. All starting materials and reagents were commercially available 
and were used without further purification unless is indicated. 1H NMR 
spectra (250, 300 and 500 MHz) and 13C NMR spectra (63, 75 and 125 
MHz) were measured in deuterated solvents. J values are given in Hertz. 
NMR assignments were carried out by a combination of 1 D, COSY, and 
DEPT-135 experiments. FT-IR spectra were recorded as NaCl plates or 
KBr discs in a PerkinElmer Two FTIR spectrometer with attenuated total 
reference. [α]D
20 = values are given in 10−1 deg cm2 g−1. MilliQ deionized 






water was used in all the buffers. All procedures involving the use of ion-
exchange resins were carried out at room temperature using Milli-Q 
deionized water. Amberlite IR-120 (H+) (cation exchanger) was washed 
alternately with water, 10% NaOH, water, 10% HCl, and finally water 
before use. The spectroscopic measurements were made on a Varian 
Cary 100 UV-Vis spectrophotometer with a 1 cm path length cell fitted 
with a Peltier temperature controller. 
Methyl (3R,4S,5R)-5-azido-3,4-(O-isopropyliden)cyclohex-1-ene-1-
carboxylate (7)  To a stirred solution of 2,2-dimethoxypropane (12 mL, 
4.69 mmol) and camphorsulfonic acid (109 mg, 0.47 mmol), under argon 
and at room temperature, diol 6 (1.0 g, 4.69 mmol) was added. The 
resulting mixture was stirred at room temperature for 4 h, diluted with 
diethyl ether and neutralized with saturated NaHCO3. The organic layer 
was separated and the aqueous layer was extracted with diethyl ether 
(×3). The combined organic extracts were dried (anh. Na2SO4), filtered 
and concentrated under reduced pressure. The resulting residue was 
purified by flash chromatography, eluting with (30:70) ethyl 
acetate/hexane, to give acetal 7 (635 mg, 54%), as a colorless oil. [α]D
20 = 
–156.9º (c = 1.0 in CHCl3). 
1H NMR (250 MHz, CDCl3): δ = 6.85 (m, 1 H, 
H2), 4.63 (m, 1 H, H3), 4.06 (dd, J = 6.2 and 8.0 Hz, 1 H, H4), 3.70 (s, 3 
H, OCH3), 3.60 (td, J = 4.7 and 8.5 Hz, 1 H, H5), 2.72 (dd, J = 4.7 and 
17.6 Hz, 1 H, H6ax), 2.14 (ddd, J = 2.0, 9.0 and 17.6 Hz, 1 H, H6eq) 1.38 
(s, 3H, CH3) and 1.32 (s, 3 H, CH3) ppm. 
13C NMR (63 MHz, CDCl3) δ: 
165.9 (C), 134.0 (C), 130.5 (CH), 110.0 (C), 76.4 (CH), 71.6 (CH), 59.3 
(CH), 52.1 (OCH3), 27.8 (CH3), 26.9 (CH2) and 25.6 (CH3) ppm. IR 
(ATR): ʋ = 2104 (N3) and 1710 (CO) cm
-1. MS (ESI) m/z = 276 (MNa+). 
HRMS calcd for C11H15N3O4Na (MNa
+): 276.0955; found, 276.0948. 
Methyl (3R,4S,5R)-5-amino-3,4-(O-isopropyliden)cyclohex-1-ene-1-
carboxylate (8)  A solution of azide 7 (635 mg, 2.51 mmol) in 
tetrahydrofuran (63 mL) and water (0.61 mL) was treated with 
triphenylphosphine (726 mg, 2.74 mmol). The resulting mixture was 
heated at reflux for 4 h. After cooling to room temperature, the solvent 
was removed under reduced pressure and the resulting residue was 
purified by flash chromatography, eluting with (10:90) 
methanol/dichloromethane, to give amine 8 (570 mg, 98%), as a yellow 
oil. [α]D
20 = –749.5º (c = 1.0 in CHCl3). 
1H NMR (250 MHz, CDCl3) δ: 6.77 
(m, 1 H; H2), 4.54 (t, J = 4.6 Hz, 1 H; H3), 3.79 (dd, J = 6.4 and 7.8 Hz, 1 
H; H4), 3.62 (s, 3 H; OCH3), 2.88 (td, J = 4.6 and 8.4, 1 H; H5), 2.55 (dd, 
J = 4.5 and 17.5 Hz, 1 H; H6ax), 1.90 (dd, J = 8.9 and 17.4 Hz, 1 H; H6eq), 
1.51 (s, 2 H; 2×NH), 1.29 (s, 3 H; CH3) and 1.25 (s, 3 H; CH3) ppm. 
13C 
NMR (63 MHz, CDCl3) δ: 166.4 (C), 133.7 (CH), 131.5 (C), 109.1 (C), 
79.1 (CH), 71.5 (CH), 51.8 (CH), 49.3 (OCH3), 30.0 (CH2), 27.9 (CH3) 
and 25.6 (CH3) ppm. IR (ATR): ʋ = 3364 (NH) and 1710 (CO) cm
-1. MS 




isopropyliden)cyclohex-1-ene-1-carboxylate (9b)  A suspension of 
amine 8 (103.5 mg, 0.46 mmol), 4Å molecular sieves (103 mg) and 
sodium acetate (75.5 mg, 0.92 mmol) in dry methanol (2.3 mL), at room 
temperature and under inert atmosphere, was treated with 2-
naphthaldehyde (72 mg, 0.46 mmol) and sodium cyanoborohydride (58 
mg, 0.92 mmol). The reaction mixture was stirred at room temperature 
for 18 h and then filtered. The filtrate and the washings were 
concentrated under reduced pressure. The resulting residue was purified 
by flash chromatography, eluting with (50:50) ethyl acetate/hexane, to 
give the amine 9b (120.4 mg, 72%), as a yellow oil. [α]D
20 = 100.3º (c = 
1.4 in CHCl3). 
1H NMR (300 MHz, CDCl3): δ = 7.80 (m, 3 H; 3×ArH), 7.75 
(s, 1 H; ArH), 7.46 (m, 3 H; 3×ArH), 6.91 (m, 1 H; H2), 4.65 (t, J = 4.1 Hz; 
1 H, H3), 4.09 (m, 1 H; H4), 4.08 (d, J = 13.7 Hz, 1 H; NCHH), 3.95 (d, J 
= 13.7 Hz, 1 H; NCHH), 3.75 (s, 3 H; OCH3), 2.912.82 (m, 2 H; 
H5+H6ax), 2.19 (br s, 1 H; NH), 2.152.05 (m, 1 H; H6eq), 1.38 (s, 3 H; 
CH3) and 1.35 (s, 3 H; CH3) ppm. 
13C NMR (75 MHz, CDCl3): δ = 166.7 
(C), 137.5 (C), 133.9 (CH), 133.4 (C), 132.7 (C), 131.7 (C), 128.2 (CH), 
127.7 (2×CH), 126.4 (2×CH), 126.0 (CH), 125.6 (CH), 109.4 (C), 77.5 
(CH), 71.8 (CH), 54.7 (CH), 52.1 (OCH3), 51.5 (NCH2), 28.0 (CH3), 27.3 
(CH2) and 25.9 (CH3) ppm. IR (ATR): ʋ = 3259 (NH) and 1718 (CO) cm
-1. 




yl)methylaminocyclohex-1-ene-1-carboxylate (10b)  A solution of 
acetal 9b (117 mg, 0.32 mmol) in ethanol (2.2 mL) and hydrochloric acid 
(0.09 mL, 6 M) was heated at 60 ºC for 4 h. After cooling to room 
temperature, the solvent was removed under reduced pressure and the 
resulting residue was purified by flash chromatography, eluting with 
(10:90) methanol/dichloromethane, to give diol 10b (71 mg, 69%), as a 
colorless oil. [α]D
20  = –87.7º (c = 1.0 in CH3OH). 
1H NMR (250 MHz, 
CD3OD): δ = 7.92 (s, 1 H; ArH), 7.76 (m, 3 H; 3×ArH), 7.52 (d, J = 8.3 Hz, 
1 H; ArH), 7.40 (dd, J = 3.0 and 5.8 Hz, 2 H; 2×ArH), 6.77 (d, J = 3.1 Hz, 
1 H; H2), 4.36 (d, J = 13.4 Hz, 1 H; CHH), 4.29 (d, J = 13.4 Hz, 1 H; 
CHH), 4.22 (m, 1 H; H3), 3.63 (s, 3 H; OCH3), 3.35 (m, 1 H; H4), 3.18 (m, 
1 H; H5), 2.96 (dd, J = 4.6 and 17.3 Hz, 1 H; H6eq) and 2.40 (dd, J = 10.3 
and 16.6 Hz, 1 H; H6ax) ppm. 
13C NMR (63 MHz, CD3OD): δ = 167.6 (C), 
137.7 (CH), 134.8 (C), 134.6 (C), 131.0 (C), 130.5 (CH), 130.0 (CH), 
129.1 (CH), 128.7 (CH), 127.9 (CH), 127.7 (C), 127.6 (2×CH), 70.6 (CH), 
66.4 (CH), 54.4 (OCH3), 52.7 (CH), 50.0 (CH2) and 28.6 (CH2) ppm. IR 
(ATR): ʋ = 3349 (NH+OH) and 1710 (CO) cm-1. MS (ESI) m/z = 328 
(MH+). HRMS calcd for C19H22NO4 (MH
+): 328.1543; found, 328.1547. 
Sodium (3R,4S,5R)-3,4-dihydroxy-5-(naphth-2-
yl)methylaminocyclohex-1-ene-1-carboxylate (4b) – A solution of 
ester 10b (65.3 mg, 0.20 mmol) in THF (2 mL) was treated with an 
aqueous solution of sodium hydroxide (0.4 mL, 0.20 mmol, 0.5 M). The 
resulting mixture was stirred at room temperature for 30 min and then 
MilliQ water was added. The organic solvent was removed under 
reduced pressure and the resulting aqueous solution was washed with 
diethyl ether (×2) and lyophilized to give the sodium salt 4b (64.3 mg, 
96%), as a yellow foam. [α]D
20 = –66.7º (c = 1.0 in CH3OH). 
1H NMR (250 
MHz, CD3OD): δ = 7.74 (m, 4 H; 4×ArH), 7.41 (m, 1 H; ArH), 7.35 (m, 2 
H; 2×ArH), 6.47 (m, 1 H; H2), 4.13 (t, J = 4.2 Hz, 1 H; H3), 4.02 (d, J = 
13.0 Hz, 1 H; NCHH), 3.80 (d, J = 13.0 Hz, 1 H; NCHH), 3.46 (ddd, J = 
1.9, 4.4 and 10.3 Hz, 1 H; H4), 2.93 (m, 2 H; H5+CHH-6) and 2.02 (m, 1 
H; CHH-6) ppm. 13C NMR (63 MHz, CD3OD): δ = 175.6 (C), 138.8 (C), 
138.3 (C), 134.9 (C), 134.2 (C), 131.2 (CH), 129.2 (CH), 128.7 (CH), 
128.6 (CH), 128.0 (CH), 127.7 (CH), 127.1 (CH), 126.7 (CH), 73.6 (CH), 
67.3 (CH), 53.8 (CH), 51.8 (CH2) and 32.5 (CH2) ppm. IR (ATR): ʋ = 
3301 (NH+OH) and 1644 (CO) cm-1. MS (ESI) m/z = 336 (MH+). HRMS 
calcd for C18H19NNaO4 (MH
+): 336.1206; found, 336.1203. 
Methyl (3R,4S,5R)-5-(1H-indol-5-yl)methylamino-3,4-(O-
isopropyliden)cyclohex-1-ene-1-carboxylate (9c) – A suspension of 
amine 8 (93 mg, 0.41 mmol), 4Å molecular sieves (93 mg) and sodium 
acetate (67 mg, 0.82 mmol) in dry metanol (2.1 mL), at room temperature 
and under inert atmosphere, was treated with indol-5-carboxaldehyde (59 
mg, 0.41 mmol) and sodium cyanoborohydride (51 mg, 0.82 mmol). The 
resulting mixture was stirred at room temperature for 18 h and filtered. 
The filtrate and the washings were concentrated under reduced pressure. 
The resulting residue was purified by flash chromatography, eluting with 
(50:50) ethyl acetate/hexane, to give amine 9c (62 mg, 42%), as a 
colorless oil. [α]D
20 = –87.3º (c = 1.1 in CHCl3). 1H NMR (300 MHz, 
CDCl3): δ = 8.37 (br s, 1 H; NH), 7.56 (s, 1 H; ArH), 7.32 (d, J = 8.3 Hz, 1 
H; ArH), 7.18 (t, J = 3.0 Hz, 1 H; ArH), 7.13 (d, J = 8.4 Hz, 1 H; ArH), 
6.91 (m, 1 H; ArH), 6.49 (m, 1 H; H2), 4.65 (m, 1 H; H3), 4.10 (m, 1 H; 
H4), 4.07 (d, J = 13.0 Hz, 1 H; NCHH), 3.88 (d, J = 13.0 Hz, 1 H; NCHH), 
3.77 (s, 3 H; OCH3), 2.95–2.82 (m, 2 H; H5+H6ax), 2.29 (br s, 1 H; NH), 






2.12 (dd, J = 6.8 and 15.6 Hz, 1 H; H6eq), 1.37 (s, 3 H; CH3) and 1.33 (s, 
3 H; CH3) ppm. 
13C NMR (75 MHz, CDCl3): δ = 166.9 (C), 135.2 (C), 
134.1 (CH), 131.8 (C), 130.9 (C), 128.1 (C), 124.7 (CH), 122.6 (CH), 
120.3 (CH), 111.2 (CH), 109.6 (C), 102.5 (CH), 77.4 (CH), 71.9 (CH), 
54.7 (CH), 52.2 (OCH3), 52.0 (NCH2), 28.1 (CH3), 27.2 (CH2) and 26.1 
(CH3) ppm. IR (ATR): ʋ = 3383 (NH) and 1710 (CO) cm
-1. MS (ESI) m/z 
= 357 (MH+). HRMS calcd for C20H25N2O4 (MH
+): 357.1809; found, 
357.1800. 
Methyl (3R,4S,5R)-3,4-dihydroxy-5-(1H-indol-5-
yl)methylaminocyclohex-1-ene-1-carboxylate (10c) – A solution of 
acetal 9c (62.1 mg, 0.17 mmol) in ethanol (1.1 mL) and hydrochloric acid 
(0.05 mL, 6 M) was heated at 60 ºC for 4 h. After cooling to room 
temperature, the solvent was removed under reduced pressure and the 
resulting residue was purified by flash chromatography, eluting with 
(10:90) methanol/dichloromethane, to give diol 10c (33.8 mg, 63%), as a 
yellow foam. [α]D
20 = –136.6º (c = 1.1 in CH3OH). 1H NMR (300 MHz, 
CD3OD): δ = 7.75 (s, 1 H; ArH), 7.49 (d, J = 8.3 Hz, 1 H; ArH), 7.33 (s, 1 
H; ArH), 7.27 (d, J = 8.4 Hz, 1 H; ArH), 6.94 (d, J = 4.0 Hz, 1 H; ArH), 
6.49 (d, J = 3.0 Hz, 1 H; H2), 4.46 (d, J = 13.6 Hz, 1 H; NCHH), 4.41 (d, J 
= 13.6 Hz, 1 H; NCHH), 4.34 (m, 1 H; H3), 3.86 (dd, J = 3.3 and 11.0 Hz, 
1 H; H4), 3.79 (s, 3 H; OCH3), 3.50 (m, 1 H; H5), 3.09 (dd, J = 5.5 and 
17.3 Hz, 1 H; H6ax) and 2.49 (dd, J = 2.9 and 14.3 Hz, 1 H; H6eq) ppm. 
13C NMR (75 MHz, CD3OD): δ = 167.1 (C), 137.5 (2×CH), 129.9 (C), 
129.3 (C), 126.9 (CH), 123.4 (CH), 123.1 (CH), 121.9 (C), 112.8 (CH), 
102.4 (C), 70.0 (CH), 66.0 (CH), 53.5 (CH), 53.4 (OCH3), 50.7 (NCH2) 
and 28.3 (CH2) ppm. IR (ATR): ʋ = 3338 (NHOH) and 1706 (CO) cm
-1. 
MS (ESI) m/z = 317 (MH+). HRMS calcd for C17H21N2O4 (MH
+): 
317.1496; found, 317.1499.  
Sodium (3R,4S,5R)-3,4-dihydroxy-5-(1H-indol-5-
yl)methylaminocyclohex-1-ene-1-carboxylate (4c) – A solution of 
ester 10c (80.1 mg, 0.25 mmol) in THF (2.5 mL) was treated with an 
aqueous solution of sodium hydroxide (0.5 mL, 0.25 mmol, 0.5 M). The 
resulting mixture was stirred at room temperature for 30 min and then 
MilliQ water was added. The organic solvent was removed under 
reduced pressure and the resulting aqueous solution was washed with 
diethyl ether (×2) and lyophilized to give the sodium salt 4c (73.7 mg, 
91%), as a yellow foam. [α]D
20 = 54.1º (c = 1.0 in H2O). 1H NMR (300 
MHz, D2O): δ = 7.54 (s, 1 H; ArH), 7.46 (d, J = 8.3 Hz, 1 H; ArH), 7.34 (s, 
1 H; ArH), 7.14 (d, J = 8.3 Hz, 1 H; ArH), 6.51 (br s, 1 H; ArH), 6.44 (d, J 
= 3.1 Hz, 1 H; H2), 4.25 (m, 1 H; H3), 3.86 (d, J = 12.7 Hz, 1 H; NCHH), 
3.66 (d, J = 12.7 Hz, 1 H; NCHH), 3.59 (dd, J = 3.7 and 9.6 Hz, 1 H; H4), 
2.90 (m, 1 H; H5), 2.80 (dd, J = 5.0 and 17.6 Hz, 1 H; H6ax) and 2.04 (dd, 
J = 8.8 and 17.6 Hz, 1 H; H6eq) ppm. 
13C NMR (75 MHz, D2O): δ = 178.1 
(C), 139.3 (C), 137.5 (C), 132.8 (CH), 132.7 (C), 130.1 (C), 128.7 (CH), 
125.0 (CH), 122.8 (CH), 114.2 (CH), 103.5 (CH), 73.8 (CH), 68.3 (CH), 
54.4 (CH), 52.5 (NCH2) and 32.6 (CH2) ppm. IR (ATR): ʋ = 3395 (NH), 
3286 (OH) and 1654 (CO) cm1. MS (ESI) m/z = 325 (MH+). HRMS calcd 
for C16H18N2O4Na (MH
+): 325.1159; found, 325.1153. 
Methyl (3R,4S,5R)-5-amino-3,4-dihydroxycyclohex-1-ene-1-
carboxylate [methyl 5-aminoshikimate] (11)  A solution of azide 6[4] 
(75 mg, 0.35 mmol) in tetrahydrofuran (8.8 mL) and water (0.085 mL) 
was treated with triphenylphosphine (101 mg, 0.38 mmol). The resulting 
mixture was heated under reflux for 4 h. After cooling to room 
temperature, the solvents were concentrated under reduced pressure. 
The resulting residue was purified by flash chromatography, eluting with 
(20:80) methanol/dichloromethane, to give the amine 11[6] (50.2 mg, 
77%), as a yellow solid. m.p., 149.8150.1 ºC. [α]D
20 = 179.7º (c = 1.1 in 
CH3OH). 
1H NMR (300 MHz, CD3OD): δ = 6.91 (m, 1 H; H2), 4.33 (t, J = 
4.4 Hz, 1 H; H3), 3.80 (s, 3 H; OCH3), 3.47 (dd, J = 4.3 and 9.8 Hz, 1 H; 
H4), 3.14 (td, J = 5.5 and 9.4 Hz, 1 H; H5), 2.83 (dd, J = 5.4 and 17.9 Hz, 
1 H; H6ax) and 2.152.05 (ddd, J = 2.5, 8.7 and 17.9 Hz, 1 H; H6eq) ppm. 
13C NMR (75 MHz, CD3OD): δ = 168.5 (C), 138.2 (CH), 131.8 (C), 74.5 
(CH), 66.8 (CH), 52.5 (OCH3), 48.3 (CH) and 32.9 (CH2) ppm. IR (ATR): 
ʋ = 3441 (NH) and 1707 (CO) cm-1. MS (ESI) m/z = 188 (MH+). HRMS 
calcd for C8H14NO4 (MH
+): 188.0917; found, 188.0916. 
Methyl (3R,4S,5R)-5-di(benzo[b]thiophen-5-yl)methylamino-3,4-
dihydroxycyclohex-1-eno-1-carboxylate (12a)  A solution of amine 11 
(106 mg, 0.57 mmol) and anhydrous potassium carbonate (94 mg, 0.68 
mmol) in dry acetonitrile (2.9 mL),under inert atmosphere, was treated 
with a solution of 5-(bromomethyl)benzo[b]thiophene (129.4 mg, 0.57 
mmol) in dry acetonitrile (3.2 mL). The resulting mixture was stirred at 
room temperature for 18 h and then diluted with water and chloroform. 
The organic layer was separated and the aqueous phase was extracted 
with chloroform (×2). The combined organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography, eluting with 
(30:70) ethyl acetate/hexane, to give dialkylamine 12a (87.4 mg, 32%) as 
a colourless oil. [α]D
20 = 71.1º (c = 1.2 in CHCl3). 1H NMR (250 MHz, 
CDCl3): δ = 7.80 (d, J = 8.2 Hz, 2 H; 2×ArH), 7.67 (br s, 2 H; 2×ArH), 
7.41 (dd, J = 2.9 and 5.4 Hz, 2 H; 2×ArH), 7.25 (m, 4 H; 4×ArH), 6.85 (t, J 
= 2.5 Hz, 1 H; H2), 4.40 (br s, 1 H; H3), 4.10 (m, 1 H; H4), 3.60 (d, J = 
13.0 Hz, 2 H; 2×NCHH), 3.76 (s, 3 H; OCH3), 3.58 (d, J = 13.0 Hz, 2 H; 
2×NCHH), 3.16 (m, 1H, H5), 2.86 (br d, J = 9.3 Hz, 1H, H6ax), 2.65 (br s, 
1H, OH) and 2.34 (m, 1 H; H6eq) ppm. 
13C NMR (63 MHz, CDCl3): δ = 
167.1 (C), 139.9 (CH), 138.9 (C), 135.0 (2×C), 134.8 (2×C), 132.6 (2×C), 
127.0 (2×CH), 125.3 (2×CH), 124.1 (2×CH), 123.8 (2×CH), 122.9 (2×CH), 
68.1 (CH), 65.0 (CH), 53.9 (2×NCH2), 53.6 (CH), 52.3 (OCH3) and 22.5 
(CH2) ppm. IR (ATR): ʋ = 3409 (OH) and 1707 (CO) cm
1. MS (ESI) m/z 
= 480 (MH+). HRMS calcd for C26H26NO4S2 (MH
+): 480.1298; found, 
480.1297. 
Sodium (3R,4S,5R)-5-di(benzo[b]thiophen-5-yl)methylamino-3,4-
dihydroxycyclohex-1-eno-1-carboxylate (5a)  A solution of ester 12a 
(25.1 mg, 0.052 mmol) in THF (0.5 mL) was treated with an aqueous 
solution of sodium hydroxide (0.10 mL, 0.5 M). The resulting mixture was 
stirred at room temperature for 30 min and then MilliQ water was added. 
The organic solvent was removed under reduced pressure and the 
resulting aqueous solution was washed with diethyl ether (×2) and 
lyophilized to give the sodium salt 5a (24 mg, 94%), as a white solid. m.p., 
184.5185.0 ºC. [α]D
20 = 73.9º (c = 1.4 in CH3OH). 1H NMR (250 MHz, 
CD3OD): δ = 7.65 (m, 4 H; 4×ArH), 7.36 (br d, J = 5.3 Hz, 2 H; 2×ArH), 
7.23 (d, J = 8.3 Hz, 2 H; 2×ArH), 7.16 (m, 2 H; 2×ArH), 6.31 (m, 1 H; H2), 
4.13 (m, 1 H; H3), 3.89 (d, J = 13.0 Hz, 2 H; 2×NCHH), 3.66 (m, 1 H; H4), 
3.58 (d, J = 13.0 Hz, 2 H; 2×NCHH), 3.05 (m, 1 H; H5), 2.68 (dd, J = 4.5 
and 17.8 Hz, 1 H; H6eq) and 2.28 (dd, J = 10.8 and 17.8 Hz, 1 H; H6ax) 
ppm. 13C NMR (63 MHz, CD3OD): δ = 175.8 (C), 141.2 (2×C), 140.5 (C), 
139.8 (2×C), 137.4 (2×C), 130.1 (CH), 127.6 (2×CH), 126.6 (2×CH), 
125.0 (2×CH), 124.8 (2×CH), 123.2 (2×CH), 71.4 (CH), 67.6 (CH), 55.0 
(2×NCH2), 32.8 (CH) and 14.5 (CH2) ppm. IR (ATR): ʋ = 3397 (OH) and 
1644 (CO) cm-1. MS (ESI) m/z = 488 (MH+). HRMS calcd for 
C25H23NO4S2Na (MH
+): 488.0961; found, 488.0949. 
Methyl (3R,4S,5R)-5-di(naphth-2-yl)methylamino-3,4-
dihydroxycyclohex-1-eno-1-carboxylate (12b)  A solution of amine 
11 (103 mg, 0.55 mmol) and anhydrous potassium carbonate (91.2 mg, 
0.66 mmol) in dry acetonitrile (2.8 mL), under inert atmosphere, was 
treated with a solution of 5-(bromomethyl)naphthalene (121.6 mg, 0.55 
mmol) in dry acetonitrile (3.1 mL). The resulting mixture was stirred at 
room temperature for 18 h and then diluted with water and chloroform. 
The organic layer was separated and the aqueous phase was extracted 
with chloroform (×2). The combined organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. The 
resulting residue was purified by flash chromatography, eluting with 
(40:60) ethyl acetate/hexane, to give dialkylamine 12b (80 mg, 31%) as a 







20 = 96.4º (c = 1.1 in CH3OH). 1H NMR (300 MHz, 
CD3OD): δ = 7.72 (m, 8 H; 8×ArH), 7.447.35 (m, 6 H; 6×ArH), 6.70 (dd, 
J = 1.9 and 5.3 Hz, 1 H; H2), 4.23 (t, J = 4.6 Hz, 1 H; H3), 3.88 (d, J = 
13.5 Hz, 2 H; 2×NCHH), 3.72 (s, 3 H; OCH3), 3.59 (m, 3 H; 2×NCHHH4), 
3.14 (td, J = 5.3 and 10.6 Hz, 1 H; H5), 2.69 (dd, J = 5.2 and 17.9 Hz, 1 
H; H6ax) and 2.20 (ddd, J = 1.9, 10.6 and 17.6 Hz, 1 H; H6eq) ppm. 
13C 
NMR (75 MHz, CD3OD): δ = 168.5 (C), 138.5 (2×C), 136.9 (CH), 134.7 
(2×C), 134.2 (2×C), 133.2 (C), 129.0 (2×CH), 128.6 (7×CH), 128.0 
(2×CH), 126.9 (2×CH), 126.6 (2×CH), 70.9 (CH), 67.1 (CH), 55.1 
(2×NCH2), 54.9 (CH), 52.5 (OCH3) and 26.1 (CH2) ppm. IR (ATR): ʋ = 
3411 (OH) and 1711 (CO) cm1. MS (ESI) m/z = 468 (MH+). HRMS calcd 
for C30H30NO4 (MH
+): 468.2169; found, 468.2168. 
Sodium (3R,4S,5R)-5-di(naphth-2-yl)methylamino-3,4-
dihydroxycyclohex-1-eno-1-carboxylate (5b)  A solution of ester 12b 
(67 mg, 0.14 mmol) in THF (1.4 mL) was treated with an aqueous 
solution of sodium hydroxide (0.28 mL, 0.5 M). The resulting mixture was 
stirred at room temperature for 30 min and then MilliQ water was added. 
The organic solvent was removed under reduced pressure and the 
resulting aqueous solution was washed with diethyl ether (×2) and 
lyophilized to give the sodium salt 5b (64.5 mg, 97%), as a white solid. 
m.p., 161.8162.0 ºC. [α]D
20 = 107.4º (c = 1.1 in CH3OH). 1H NMR (300 
MHz, CD3OD): δ = 7.54 (m, 8 H; 8×ArH), 7.29 (d, J = 8.5 Hz, 2 H; 2×ArH), 
7.19 (m, 4 H; 4×ArH), 6.28 (dd, J = 1.7 and 5.2 Hz, 1 H; H2), 4.09 (t, J = 
4.6 Hz, 1 H; H3), 3.83 (d, J = 13.4 Hz, 2 H; 2×NCHH), 3.54 (m, 3 H; 
2×NCHHH4), 3.01 (td, J = 5.2 and 10.8 Hz, 1 H; H5), 2.67 (dd, J = 5.0 
and 17.8 Hz, 1 H; H6ax) and 2.25 (ddd, J = 1.7, 10.8 and 17.8 Hz, 1 H; 
H6eq) ppm. 
13C NMR (75 MHz, CD3OD): δ = 175.8 (C), 140.5 (C), 138.7 
(2×C), 134.8 (2×C), 134.2 (2×C), 130.0 (CH), 129.0 (2×CH), 128.6 
(6×CH), 128.1 (2×CH), 126.9 (2×CH), 126.5 (2×CH), 71.4 (CH), 67.6 
(CH), 55.3 (2×NCH2), 55.2 (CH) and 27.1 (CH2) ppm. IR (ATR): ʋ = 3380 
(OH) and 1659 (CO) cm-1. MS (ESI) m/z = 454 (MH+). HRMS calcd for 
C29H28NO4 (MH
+): 454.2013; found, 454.2012. 
Methyl (3R,4S,5R)-5-di(3-bromo-1-tert-butoxycarbonyl-1H-indol-5-
yl)methylamino-3,4-dihydroxycyclohex-1-eno-1-carboxylate (12d)  
A solution of amine 11 (60 mg, 0.32 mmol) and potassium carbonate (52 
mg, 0.38 mmol) in dry acetonitrile (1.6 mL), under argon, was treated 
with a solution of tert-butyl 3-bromo-5-(bromomethyl)-1H-indole-1-
carboxylate[23] (99 mg, 0.32 mmol) in dry acetonitrile (1.8 mL). The 
resulting mixture was stirred at room temperature for 18 h. Water was 
added and the organic layer was separated. The aqueous layer was 
extracted with chloroform (×2). The combined organic extracts were dried 
(anh. Na2SO4), filtered and concentrated under reduced pressure. The 
residue obtained was purified by flash chromatography, eluting (30:70) 
ethyl acetate/hexane, to give the dialkyl amine 12d (59 mg, 23%) as a 
colourless oil. [α]D
20 = 56.4º (c = 1.2 in CHCl3). 1H NMR (300 MHz, 
CDCl3): δ = 8.08 (d, J = 8.2 Hz, 2 H; 2×ArH), 7.61 (s, 2 H; 2×ArH), 7.37 (s, 
2 H; 2×ArH), 7.30 (d, J = 8.2 Hz, 2 H; 2×ArH), 6.88 (d, J = 4.0 Hz, 1 H; 
H2), 4.44 (br s, 1 H; H3), 4.02 (d, J = 13.0 Hz, 2 H; 2×NCHH), 3.79 (s, 3 
H; OCH3), 3.73 (m, 1 H; H4), 3.65 (d, J = 13.1 Hz, 2 H; 2×NCHH), 3.17 
(m, 1 H; H5), 2.88 (dd, J = 3.9 and 17.2 Hz, 1 H; H6eq), 2.67 (br s, 2 H; 
2×OH), 2.38 (dd, J = 12.0 and 16.4 Hz, 1 H; H6ax) and 1.57 (s, 9 H; 
3×CH3) ppm. 
13C NMR (75 MHz, CDCl3) δ: 167.1 (C), 148.9 (2×C), 135.0 
(2×C), 134.1 (2×C), 133.9 (CH), 132.6 (C), 129.7 (2×C), 126.4 (2×CH), 
125.3 (2×CH), 120.0 (2×CH), 115.6 (2×CH), 97.9 (2×C), 84.5 (2×C), 68.2 
(CH), 65.1 (CH), 54.2 (2×NCH2), 54.0 (CH), 52.3 (OCH3), 28.3 (3×CH3) 
and 22.7 (CH2) ppm. IR (ATR): ʋ = 3463 (OH), 3150 (NH), 1738 (CO) 
and 1717 (CO) cm-1. MS (ESI) m/z = 802 and 804 (MH+). HRMS calcd for 
C36H42N3O8Br2
79 (MH+): 802.1333; found, 802.1329. 
(3R,4S,5R)-5-di(3-bromo-1H-indol-5-yl)methylamino-3,4-
dihydroxycyclohex-1-eno-1-carboxylic acid (5d)  A solution of ester 
12d (61.2 mg, 0.095 mmol) and potassium carbonate (39.4 mg, 0.28 
mmol) in 75% aqueous methanol (1.4 mL) was heated under reflux for 
2.5 h. After cooling to room temperature, diethyl ether was added and the 
organic layer was separated. The aqueous phase was washed with 
diethyl ether (×2). The aqueous extract was lyophilized to give acid 5d 
(42 mg, 75%) as a white foam. [α]D
20 = 52.8º (c = 1.1 in CH3OH). 1H 
NMR (300 MHz, CD3OD): δ = 7.35 (br s, 2 H; 2×ArH), 7.26 (d, J = 8.4 Hz, 
2 H; 2×ArH), 7.17 (s, 2 H; 2×ArH), 7.13 (d, J = 8.6 Hz, 2 H; 2×ArH), 6.39 
(d, J = 5.1 Hz, 1 H; H2), 4.21 (t, J = 4.7 Hz, 1 H; H3), 3.93 (d, J = 13.0 Hz, 
2 H; 2×NCHH), 3.65 (dd, J = 4.2 and 11.0 Hz, 1 H; H4), 3.57 (d, J = 13.1 
Hz, 2 H; 2×NCHH), 3.15 (td, J = 6.0 and 13.0 Hz, 1 H; H5), 2.76 (dd, J = 
6.1 and 21.4 Hz, 1 H; H6eq) and 2.35 (dd, J = 12.5 and 21.4 Hz, 1 H; 
H6ax) ppm. 
13C NMR (75 MHz, CD3OD): δ = 175.8 (C), 140.6 (2×C), 
136.4 (2×C), 132.5 (2×C), 129.9 (CH), 127.9 (C), 125.3 (2×CH), 124.8 
(2×CH), 119.8 (2×CH), 112.9 (2×CH), 90.7 (2×C), 70.8 (CH), 67.1 (CH), 
54.9 (2×NCH2), 54.8 (CH) and 25.8 (CH2) ppm. IR (ATR): ʋ = 3333 
(OH+NH) and 1560 (CO) cm-1. MS (ESI) m/z = 585 and 587 (M−H). 
HRMS calcd for C25H22N3O8Br2
79 (M−H): 585.9983; found, 585.9984. 
Shikimate kinase assay. Both enzymes were purified and assayed as 
described previously.15,27,23 The determined kinetic parameters for Hp-SK 
and Mt-SK were Km (1) = 39  8 µM; kcat = 116  4 10
–3 s−1 and Km (1) = 
544  14 µM; kcat = 295  8 s
−1, respectively. 
Docking studies. They were carried out using program GOLD 5.2[25] and 
the enzyme geometries and the enzyme coordinates collected in the MD 
simulation studies carried out with the SK complex containing: (a) Mt-
SK/ATP/Mg+2/(6R)-6-hydroxyshikimic acid (10 ns)[23]; (b) Hp-SK/ADP/2 
(50 ns)[24]. Different snapshots obtained after 7 ns of MD for Mt-SK and 
11 ns for Hp-SK were employed. Water molecules, the product and 
(6R)-6-hydroxyshikimic acid were removed from the models. Ligand 
geometries were minimized using the AM1 Hamiltonian as implemented 
in the program Gaussian 09[28] and used as MOL2 files. Each ligand was 
docked in 25 independent genetic algorithm (GA) runs, and for each of 
these a maximum number of 100000 GA operations were performed on a 
single population of 50 individuals. Operator weights for crossover, 
mutation and migration in the entry box were used as default parameters 
(95, 95, and 10, respectively), as well as the hydrogen bonding (4.0 Å) 
and van der Waals (2.5 Å) parameters. The position of shikimate-3-
phosphate (2) and (6R)-6-hydroxyshikimic acid in both models was used 
to define the active-site and the radius was set to 7 Å. The “flip ring 
corners” flag was switched on, while all the other flags were off. The 
GOLD scoring function was used to rank the ligands in order to fitness. 
Molecular Dynamics Simulations. Ligand preparation. The ligand 
geometries of the highest score solution obtained by docking were 
minimized using a restricted Hartree–Fock (RHF) method and a 6–
31G(d) basis set, as implemented in the ab initio program Gaussian 09. 
Ligands were manually docked into the active site. The resulting 
wavefunctions were used to calculate electrostatic potential-derived 
(ESP) charges employing the restrained electrostatic potential (RESP)[29] 
methodology, as implemented in the assisted model building with energy 
refinement (AMBER)[30] suite of programs. The missing bonded and non-
bonded parameters were assigned, by analogy or through interpolation, 
from those already present in the AMBER database (GAFF).[31] 
Generation and minimization of ternary complexes. Simulations of 
inhibitor/ATP/SK complexes were carried out using the highest score 
solution obtained by docking and the enzyme geometries used in those 
docking studies. Computation of the protonation state of titratable groups 
at pH 7.0 was carried out using the H++ Web server.[32] Addition of 
hydrogen and molecular mechanics parameters from the ff03 and GAFF 
force fields, respectively, were assigned to the protein and the ligands 
using the LEaP module of AMBER Tools 14.[30-31,33] ATP and Mg2+ 
parameters used with the AMBER force field were included.[34-35]  






The complex was immersed in a truncated octahedron of 5200 TIP3P 
water molecules and neutralized by addition of chloride (Mt-SK) or 
sodium (Hp-SK) ions.[30,36-37] All systems were minimized in four stages: 
(a) initial minimization of the ligand and the closest residues of the SB 
domain (500 steps, first half using steepest descent and the rest using 
conjugate gradient); (b) minimization of the solvent and ions (5000 steps, 
first half using steepest descent and the rest using conjugate gradient); 
(c) minimization of the side chains, waters and ions (5000 steps, first half 
using steepest descent and the rest using conjugate gradient); (d) final 
minimization of the whole system (5000 steps, first half using steepest 
descent and the rest using conjugate gradient). A positional restraint 
force of 50 kcal mol–1 Å–2 was applied to those unminimized atoms during 
the first three stages (ac).  
Simulations. MD simulations were performed using the sander module 
from the AMBER 12 suite of programs. Periodic boundary conditions 
were applied and electrostatic interactions were treated using the smooth 
particle mesh Ewald method (PME)[38] with a grid spacing of 1 Å. The 
cutoff distance for the non-bonded interactions was 9 Å. The SHAKE 
algorithm[39] was applied to all bonds containing hydrogen, using a 
tolerance of 105 Å and an integration step of 2.0 fs. The minimized 
system was then heated at 300 K at 1 atm by increasing the temperature 
from 0 K to 300 K over 100 ps and by keeping the system at 300 K 
another 100 ps. A positional restraint force of 50 kcal mol–1 Å–2 was 
applied to all  carbons during the heating stage. Finally, an equilibration 
of the system at constant volume (100 ps with positional restraints of 5 
kcal mol–1 Å–2 to  alpha carbons) and constant pressure (another 100 ps 
with positional restraints of 5 kcal mol–1 Å–2 to  alpha carbons) were 
performed. The positional restraints were gradually reduced from 5 to 1 
mol–1 Å–2 (5 steps, 100 ps each), and the resulting systems were allowed 
to equilibrate further (100 ps). Unrestrained MD simulations were carried 
out for 50 ns. System coordinates were collected every 10 ps for further 
analysis. Figures depicting structures were prepared using PYMOL.[40] 
The cpptraj module in AMBER 12 was used to analyze the trajectories 
and to calculate the root-mean-square deviations (RMSD) of the protein 
and ligands during the simulation.[41] 
Vibrational Modes Calculations. The vibrational modes for the two SK 
enzyme were calculated by principal component analysis with the cpptraj 
module implemented in Amber Tools 14 from the corresponding MD 
trajectories of product release (SK/ADP/2[23-24]).[42] The main vibrational 
modes for the two SK are shown in Figures 3E and 3F. The probability 
density of the vibrational modes obtained is shown in Figure S3. 
MM/PBSA Calculations. The binding free energy for each ligand was 
calculated by the MM/PBSA26 approach implemented in Amber Tools 14 
and based on the 451 snapshots extracted every 100 ps from the 
corresponding 50 ns MD trajectories (SK/ATP/Mg2+/ligand). Only the last 
45 ns of the simulation were used. The Poisson-Boltzmann (PB) and 
Generalized Born (GB) implicit solvation models were employed. The 
latter model provided relative free energy values more in agreement with 
the relative inhibitory potency obtained experimentally. ante-MMPBSA.py 
module was used to create topology files for the complex, receptor and 
ligand and binding free energies were calulated with the MMPBSA.py 
module. 
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Enzyme dynamics: The 
asynchronous and more reduced 
opening and its more parsimonious 
motion of the shikimic acid domain of 
the Helicobacter pylori enzyme for 
catalytic turnover were exploited for 
inhibitor design selectivity. 
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